Stocksigma LogoStocksigma Logo

Dr. Lal PathLabs Reports Strong Q2 Results, Declares Interim Dividend, and Expands Overseas

Dr. Lal PathLabs reported consolidated revenue of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn, with net profit rising

Dr. Lal PathLabs Reports Strong Q2 Results, Declares Interim Dividend, and Expands Overseas

Dr. Lal PathLabs Ltd 路 Dividend 路 04 Nov 2026, 7:08 pm

Dr. Lal PathLabs Reports Strong Q2 Results, Declares Interim Dividend, and Expands Overseas Dr. Lal PathLabs reported consolidated revenue of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn, with net profit rising 27.4% YoY to INR 1,939 mn. Basic EPS expanded to INR 11.51 from INR 9.03. The Board declared a second interim dividend of INR 5 per share (50% on face value of INR 10), with a record date of 11th Nov'26. Additionally, the company approved up to INR 49.5 cr in further investments into its Dubai subsidiary to fund operations and African expansion.

Original exchange filing (PDF)

More announcements from Dr. Lal PathLabs Ltd

  • Attached 路 11 Nov 2026
  • Attached 路 10 Nov 2026
  • Attached 路 05 Nov 2026
  • Attached 路 04 Nov 2026
  • Attached 路 04 Nov 2026
  • Attached 路 04 Nov 2026
  • Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
  • Attached 路 04 Nov 2026

All Dr. Lal PathLabs Ltd announcements